卡博替尼联合纳武利尤单抗与伊匹木单抗一线治疗晚期肾细胞癌:COSMIC-313 III期最终结果与生物标志物分析
COSMIC-313 III期双盲随机研究在初治晚期透明细胞肾细胞癌患者中比较卡博替尼或安慰剂联合纳武利尤单抗与伊匹木单抗。中位随访45.0个月,三联组中位无进展生存期(PFS)长于双联组(16.6 vs 11.2个月;HR 0.82,95%CI 0.69-0.98),但总生存期(OS)无显著差异(HR 1.02,95%CI 0.85-1.23,P=0.84)。探索性生物标志物分析提示,在高水平M2样巨噬细胞患者中三联方案与显著改善的PFS和OS相关。
要点
- 三联方案较双联方案显著延长PFS(16.6 vs 11.2个月;HR 0.82,95%CI 0.69-0.98)。
- 总生存期无显著差异(HR 1.02,95%CI 0.85-1.23,P=0.84)。
- 3/4级治疗相关不良事件发生率三联组75%、双联组43%。
核心结论
- 长期随访结果继续显示,在纳武利尤单抗与伊匹木单抗基础上加用卡博替尼可改善PFS。
- 未观察到OS获益,也未发现新的安全性信号。
- 探索性生物标志物分析提示,在高水平M2样巨噬细胞患者中,三联方案与显著改善的PFS和OS相关。
研究设计与样本
- III期、双盲、随机(1:1)研究,比较卡博替尼或安慰剂联合纳武利尤单抗与伊匹木单抗。
- 研究对象为初治晚期透明细胞肾细胞癌成人患者。
- 主要终点PFS的设计、参与者和结果已先前报道;次要终点为意向治疗人群的OS。
- 探索性生物标志物分析研究免疫细胞类型和基因特征与临床结局的潜在关联。
主要发现
- 中位随访45.0个月,三联组中位PFS为16.6个月,双联组为11.2个月(HR 0.82,95%CI 0.69-0.98)。
- 中位OS无显著差异(HR 1.02,95%CI 0.85-1.23,P=0.84)。
- 3/4级治疗相关不良事件发生率三联组为75%,双联组为43%。
- 在高水平M2样巨噬细胞患者中,三联方案与显著改善的PFS和OS相关。
- 三联组应答者血管生成特征升高、免疫相关通路降低;双联组应答者免疫激活强烈。
关键数值与推荐
- 中位PFS:三联组16.6个月 vs 双联组11.2个月(HR 0.82,95%CI 0.69-0.98)。
- 中位OS:HR 1.02,95%CI 0.85-1.23,P=0.84。
- 3/4级治疗相关不良事件:三联组75%,双联组43%。
临床怎么用
- 对于初治晚期透明细胞肾细胞癌,卡博替尼联合纳武利尤单抗与伊匹木单抗可考虑作为改善PFS的治疗选择。
- 该方案未显示OS获益,临床决策需综合权衡PFS获益与更高的3/4级治疗相关不良事件风险。
- 高水平M2样巨噬细胞可能作为筛选三联方案获益人群的探索性生物标志物。
局限性
- 生物标志物分析为探索性,其结果需进一步验证。
- OS未观察到显著获益。
- 三联方案3/4级治疗相关不良事件发生率较高(75% vs 43%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary results from COSMIC-313 demonstrated significantly longer progression-free survival (PFS) with first-line cabozantinib plus nivolumab and ipilimumab versus placebo plus nivolumab and ipilimumab in patients with advanced renal cell carcinoma. Final efficacy and safety results, as well as data from exploratory biomarker analyses, are reported here. PATIENTS AND METHODS: The design, participants, and primary-endpoint PFS outcomes have been reported previously for this phase III, double-blind, randomized (1 : 1) study of cabozantinib or placebo plus nivolumab and ipilimumab in adults with previously untreated, advanced clear cell renal cell carcinoma. The secondary endpoint was overall survival (OS) in the intention-to-treat population. Exploratory biomarker analyses investigated the potential association between immune cell types and gene signatures with clinical outcomes. RESULTS: After a median follow-up of 45.0 months, the updated median PFS in the cabozantinib (triplet) arm was longer than in the placebo (doublet) arm (16.6 versus 11.2 months; hazard ratio 0.82, 95% confidence interval 0.69-0.98). There was no significant difference in median OS (hazard ratio 1.02, 95% confidence interval 0.85-1.23, P = 0.84), and the safety profile was consistent with the earlier analysis (grade 3/4 treatment-related adverse events occurred in 75% and 43% of patients in the triplet and doublet arms, respectively). In patients with higher levels of M2-like macrophages, the triplet regimen was associated with significantly improved PFS and OS compared with the doublet regimen. Responders in the triplet arm exhibited elevated angiogenic signatures and reduced immune-related pathways, while responders in the doublet arm had robust immune activation. CONCLUSIONS: Long-term results from COSMIC-313 continue to demonstrate a PFS benefit with the addition of cabozantinib to nivolumab and ipilimumab. There was no OS benefit and no new safety signals were observed. Exploratory biomarker analyses suggest adding cabozantinib to nivolumab and ipilimumab improves survival in patients with high levels of M2-like macrophages.
引用
- Motzer RJ, Albiges L, Treviño Aguirre SA, et al. Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study. Ann Oncol. 2026. PMID: 41720427. doi:10.1016/j.annonc.2026.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。